Diabetes is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years.
As of this writing, Senseonics has an unbelievably low share price. For whatever reasons, market makers have manipulated the share price lower. This is easier to do with low volumes of trading such as Senseonics has had. This presents a MASSIVE buying opportunity for those smart enough to recognize it. For comparative purposes, we’ll show you a historical chart for a competitor, Dexcom. You’ll see that in 2009 Dexcom was trading at around $1.36. It’s now trading at over $200! If you had invested $10,000 in Dexcom at that time, your investment would now be worth over $1.5 Million. If you didn’t catch it at the bottom, and you bought at 5 times that price ($6.80), your $10,000 would now be worth $300.000. Even if you bought it at 10 times the low price ($13.60), your $10k investment would be worth over $150k. Clearly, the sooner you bought in (when the risk and uncertainty was higher), the more exponential your return. But even at $50 or $100, Dexcom was clearly a fantastic investment at the time.
We believe Senseonics is as big of an opportunity as Dexcom was in 2009, with a better product and even more potential.
Here are a few main bullet points to keep in mind when evaluating your decision:
The current field of competitors now includes Dexcom (NASDAQ: DXCM), Medtronic(NYSE: MDT), and Abbot Laboratories (NYSE: ABT). Of these, Eversense by Senseonics is the only implantable device, allowing the sensor to be changed every 90 or 180 days (365 day sensor comingEversense is also the most accurate. For an academic comparison of the CGM alternatives, go here:
Here’s a video of a comparison between Eversense and one of the main competitors, Dexcom’s G6 system:
We are in the midst of a sea change in medical technology. Constant Glucose Monitors (CGM for short) are the future of diabetic treatment.